Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382015 · ClinicalTrials.gov registry record · NA
Effect of BKR-013 on Average Daily Glucose Levels
A NA study, sponsored by BioKier.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03382015 is a NA study that has completed, run by BioKier. The registered enrollment target is 14 participants.
The verdict
NCT03382015, a NA study, has completed, sponsored by BioKier.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration. Subjects will serve as their own controls in this crossover design, and ADG will be compared while a subject is on active test product versus while they received placebo test product.
Interventions
- OTHER BKR-013 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382015
The ClinicalTrials.gov registry entry for NCT03382015 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioKier, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKR-013 or Placebo is the first listed.
NCT03382015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03382015 about?
NCT03382015 is a clinical study titled "Effect of BKR-013 on Average Daily Glucose Levels". The purpose of this study is to evaluate the effect of BKR-013 on average daily glucose (ADG) levels in type 2 diabetes (T2D) subjects during 28 days of either placebo or active test product administration. Subjects will serve as their own controls in this crossover design, and ADG will be compared ...
What is the current status of trial NCT03382015?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-01-09. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT03382015?
The interventions under investigation include: BKR-013 or Placebo (OTHER).
Who is sponsoring clinical trial NCT03382015?
This trial is sponsored by BioKier, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.